44 Intermittent Versus Continuous Maximal Androgen Blockade in Metastatic (D2) Prostate Cancer Patients. A Randomized Trial

Mottet, N.; Goussard, Marion; Loulidi, Salim; Wolff, J. M.

doi:10.1016/s1569-9056(09)60052-x

Cited by 8 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We identified and reviewed publications from 25 IAD studies; of these, 13 were selected for the present literature review based on their relevance to assess safety and tolerability of IAD (Tables 2,3). Of these 13 studies, eight were randomized , active-controlled studies comparing IAD with CAD (Table 2; n = 68 to 1386 patients), 28,29,[31][32][33][34][35][36][37][38][39] and five were observational, non-randomized studies ( Table 3; n = 19 to 250 patients). 9,[40][41][42][43] Of these eight active-controlled studies, two 31,32 were published in full, whereas preliminary results have been reported in abstract format for the remaining six studies.…”

Section: Resultsmentioning

confidence: 99%

“…However, a decrease in side-effects as a result of the hormonal deprivation was reported in all cases during the off-therapy period; hot flushes, an early androgen deprivation side-effect, was statistically significant improved in the off-treatment period. 41 Finally, no differences in QoL in IAD and CAD treatment groups have been observed in studies carried out by Mottet et al 39 and Langenhuijsen et al 36…”

Section: Qolmentioning

confidence: 91%

“…Of the nine studies that evaluated QoL, four showed a QoL benefit in patients treated with IAD, 28,38,42,43 whereas the remaining five did not show any significant difference between IAD and CAD. 31,35,36,39,41 In 2006, Spry et al carried out a study that assessed changes to QoL and testosterone dependent physiology in men receiving IAD. In this study, QoL data showed that testosterone suppression resulted in decreased global QoL, and deterioration in most function and symptom scales.…”

Section: Qolmentioning

confidence: 99%

See 2 more Smart Citations

Safety and tolerability of intermittent androgen deprivation therapy: A literature review

2012

View full text Add to dashboard Cite

Androgen deprivation therapy is commonly used in men with advanced prostate cancer; however, it is associated with many short‐ and long‐term side‐effects. Intermittent androgen deprivation therapy was first suggested as an alternative regimen in the early 1990s and is now part of treatment guidelines as a result of its ability to reduce adverse events associated with continuous androgen deprivation therapy without decreasing its efficacy. Although many publications evaluated intermittent androgen deprivation therapy's efficacy, the safety and tolerability information of this regimen is relatively limited. The goal of this literature review was to analyze clinical trials that have reported safety and tolerability data in prostate cancer patients treated with intermittent androgen deprivation therapy, as well as assessing quality of life outcomes. A literature search was carried out using biomedical and pharmaceutical databases for published information comparing intermittent androgen deprivation therapy with continuous androgen deprivation therapy. A total of 13 randomized and non‐randomized studies were selected and reviewed based on their relevance to the safety, tolerability and quality of life of intermittent androgen deprivation therapy. Benefits for intermittent androgen deprivation therapy were observed for the short‐term side‐effects (hot flushes and sexual functions) mainly during the off‐treatment phase, whereas the data for the long‐term side‐effects were not as conclusive. Quality of life evaluations are more in support of intermittent androgen deprivation therapy. Although there are some safety, tolerability and quality of life benefits associated with intermittent androgen deprivation therapy, the overall evidence is still limited.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Qolmentioning

confidence: 91%

Section: Qolmentioning

confidence: 99%

See 1 more Smart Citation

Safety and tolerability of intermittent androgen deprivation therapy: A literature review

2012

View full text Add to dashboard Cite

show abstract

Intermittent Versus Continuous Androgen Deprivation Therapy in Advanced Prostate Cancer

Klotz

2013

Curr Urol Rep

View full text Add to dashboard Cite

Intermittent androgen deprivation is increasingly employed as an alternative to continuous life long androgen deprivation therapy for men with advanced or recurrent prostate cancer. Two recent phase III trials have clarified the benefits of intermittent therapy. In men with non-metastatic disease with PSA recurrence after definitive local therapy, intermittent therapy showed equivalent survival to continuous therapy, with significant improvements in quality of life. Patients on intermittent therapy experience improved bone health, less metabolic and hematologic disturbances, fewer hot flashes, as well as improved sexual function. In men with metastatic disease, the data is less clear. The long-awaited results of SWOG 9324 comparing intermittent to continuous therapy in metastatic disease showed a trend to worse outcome in the patients with 'minimal' metastatic disease, and no difference in those with widespread bone mets. The significance of this observation is in dispute. This review also addresses practical issues in the use intermittent therapy, including patient selection, follow-up and cycling of therapy. The recent results of randomized clinical trials now establish that intermittent androgen deprivation therapy is an approach that should be considered the standard of care for most patients with non-metastatic prostate cancer requiring hormonal therapy.

show abstract

Potential Benefits of Intermittent Androgen Suppression Therapy in the Treatment of Prostate Cancer: A Systematic Review of the Literature

2010

View full text Add to dashboard Cite

44 Intermittent Versus Continuous Maximal Androgen Blockade in Metastatic (D2) Prostate Cancer Patients. A Randomized Trial

Cited by 8 publications

References 0 publications

Safety and tolerability of intermittent androgen deprivation therapy: A literature review

Safety and tolerability of intermittent androgen deprivation therapy: A literature review

Intermittent Versus Continuous Androgen Deprivation Therapy in Advanced Prostate Cancer

Potential Benefits of Intermittent Androgen Suppression Therapy in the Treatment of Prostate Cancer: A Systematic Review of the Literature

Contact Info

Product

Resources

About